If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming is inconsistent across suppliers and publications |
| Reported sequence | Ac-LKKTETQ | Corresponds to residues 17-23 of the parent protein |
| Frequently cited registry number | 77591-33-4 | Associated with full-length thymosin beta-4 rather than the fragment |
| Common supplied form | Freeze-dried solid | Often presented as an acetate or trifluoroacetate salt |
| Regulatory treatment | Varies by country | Frequently handled as a research chemical; not broadly approved as a therapeutic |
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
== Toxicity rates == In earlier years it was thought that apamin was a rather nontoxic compound (LD50 = 15 mg/kg in mice) compared to the other compounds in bee venom. The current lethal dose values of apamin measured in mice are given below. There are no data known specific for humans. Intraperitoneal (mouse) LD50: 3.8 mg/kg Subcutaneous (mouse) LD50: 2.9 mg/kg Intravenous (mouse) LD50: 4 mg/kg Intracerebral (mouse) LD50: 1800 ng/kg Parenteral (mouse) LD50: 600 mg/kg
== Cannabinoids == Cannabinoids are the compounds found in cannabis, which is a euphoriant and hallucinogenic drug prepared from the dried leaves of the strong-smelling plant Cannabis sativa. It includes synthetic cannabinoids (spice, K2), and tetrahydrocannabinol (THC, Delta-8).
After Joe Biden announced Deb Haaland as his nominee for U.S. Interior Secretary, Stansbury announced her campaign for the special election to fill the seat. In the first round of voting by the state Democratic committee, Stansbury placed second after state Senator Antoinette Sedillo Lopez and automatically advanced to the runoff. In the second round of voting, she defeated Sedillo Lopez by six votes. As no Republican had represented the district since 2009, The Santa Fe New Mexican labeled her "a heavy favorite". She defeated state Senator Mark Moores and former state Lands Commissioner Aubrey Dunn Jr. in the June 1 election in a landslide. Her margin of victory was slightly larger than President Biden's 23-point victory in the district in 2020, and significantly larger than Deb Haaland's in 2020 for the House.
Sources: en.wikipedia.org
Eurogentec is a biotechnology supplier, based in Belgium, that specializes in genomics and proteomics kits, reagents, and certain biologics. It was founded in 1985 as a spin-off from the University of Liège. Eurogentec operates two licensed contract manufacturing organization facilities in Belgium which produce custom biologic and oligonucleotide products mainly for European pharmaceutical companies, but also holds a license from the U.S. FDA to export a commercial protein product to the U.S.. These products are used to diagnose and treat various conditions.
The newest formulation to come out was in 2014 when zohydro, an increased dosage formula of hydrocodone, was released; this is so far the strongest hydrocodone formulation created for pain management, on par with a moderate dose of oxycodone .
== Medical uses == Varicella vaccine is 70% to 90% effective for preventing varicella and more than 95% effective for preventing severe varicella. Follow-up evaluations have taken place in the United States of children immunized that revealed protection for at least 11 years. Studies were conducted in Japan which indicated protection for at least 20 years. People who do not develop enough protection when they get the vaccine may develop a mild case of the disease when in close contact with a person with chickenpox. In these cases, people show very little sign of illness. This has been the case of children who get the vaccine in their early childhood and later have contact with children with chickenpox. Some of these children may develop mild chickenpox also known as breakthrough disease. Another vaccine, known as zoster vaccine, is simply a larger-than-normal dose of the same vaccine used against chickenpox and is used in older adults to reduce the risk of shingles (also called herpes zoster) and postherpetic neuralgia, which are caused by the same virus. The recombinant zoster (shingles) vaccine is recommended for adults aged 50 years and older.
Sources: en.wikipedia.org
First generation vaccines are whole-organism vaccines – either live and weakened, or killed forms. Live, attenuated vaccines, such as smallpox and polio vaccines, are able to induce killer T-cell (TC or CTL) responses, helper T-cell (TH) responses and antibody immunity. However, attenuated forms of a pathogen can convert to a dangerous form and may cause disease in immunocompromised vaccine recipients (such as those with AIDS). While killed vaccines do not have this risk, they cannot generate specific killer T-cell responses and may not work at all for some diseases. Second generation vaccines were developed to reduce the risks from live vaccines. These are subunit vaccines, consisting of specific protein antigens (such as tetanus or diphtheria toxoid) or recombinant protein components (such as the hepatitis B surface antigen). They can generate TH and antibody responses, but not killer T cell responses. RNA vaccines and DNA vaccines are examples of third generation vaccines. In 2016 a DNA vaccine for the Zika virus began testing at the National Institutes of Health. Separately, Inovio Pharmaceuticals and GeneOne Life Science began tests of a different DNA vaccine against Zika in Miami. Manufacturing the vaccines in volume was unsolved as of 2016. Clinical trials for DNA vaccines to prevent HIV are underway. mRNA vaccines such as BNT162b2 were developed in the year 2020 with the help of Operation Warp Speed and massively deployed to combat the COVID-19 pandemic.
== Emitters == Several different emitter configurations have been used for FD emitters, such as single tips, sharp blades and thin wires. Single metal tips can be made from etching wires either by periodically dipping them into molten salts or by electrolysis in aqueous solutions. Compared to other emitter types, the single tips have the advantage that they can reach the highest field strengths. In addition, well-defined geometric shape of a single tip allows accurate calculation of the potential distribution in the space between the tip and the counter electrode. For blades used as emitters, their ruggedness under the high electric field is one of their advantages. Different thin wires were also used as emitters, such as platinum wires and tungsten wires. Platinum wires are fragile, and tungsten wires are much more stable than platinum wires. Among those emitters, carbon-microneedles tungsten wires are the most widely used emitters in FD mass spectrometry.
Artemis II sent four astronauts—including the first woman, person of color, and Canadian—to circumnavigate the Moon. The 2026 FIFA World Cup was held across the U.S., Canada, and Mexico from June to July; and planned events include the 2026 midterms in November.
Sources: en.wikipedia.org
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.
Very few controlled human studies focus on the seven-residue sequence itself. Most clinical data concern the full-length protein in cardiac or ophthalmic settings. Conclusions drawn for one form should not be assumed to transfer to the other.
Detection normally relies on reversed-phase liquid chromatography paired with mass spectrometry. Chromatographic retention time establishes the expected elution window, and the mass spectrum confirms the molecular ion. Immunoassays exist but can cross-react with related peptides.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.